Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449546 | 0.84 | ALOX5AP (0.47) | ALOX5APFEN1F2RL3GPR119KDR | |
| SCHEMBL447303 | 0.84 | ALOX5AP (0.47) | ALOX5APFEN1F2RL3GPR119KDR | |
| SCHEMBL447304 | 0.84 | ALOX5AP (0.47) | ALOX5APFEN1F2RL3GPR119KDR | |
| SCHEMBL4977559 | 0.82 | ALOX5AP (0.43) | ALOX5APFEN1F2RL3LMNANPSR1 | |
| SCHEMBL4374846 | 0.82 | ALOX5AP (0.43) | ALOX5APFEN1F2RL3LMNANPSR1 | |
| SCHEMBL4370059 | 0.82 | ALOX5AP (0.43) | ALOX5APFEN1F2RL3LMNANPSR1 | |
| SCHEMBL6181081 | 0.82 | GPR119 (0.46) | ALOX5APFEN1GPR119LMNANPSR1 | |
| SCHEMBL6192737 | 0.82 | GPR119 (0.46) | ALOX5APFEN1GPR119LMNANPSR1 | |
| SCHEMBL4372549 | 0.77 | ALOX5AP (0.48) | ALOX5APFEN1F2RL3GPR119 | |
| SCHEMBL4367186 | 0.77 | ALOX5AP (0.48) | ALOX5APFEN1F2RL3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | ALOX5AP 555/4885FEN1 1212/4885F2RL3 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.